Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa 

 

Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
February 8, 2013 - (Shire) - "Shire plc today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa, a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US." Read Full Press Release

 

Posted on 14-Feb-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: